Randomized phase III study of canfosfamide (C, TLK286) plus pegylated liposomal doxorubicin (PLD) versus PLD as second-line therapy in platinum (P) refractory or resistant ovarian cancer (OC) Meeting Abstract

International Collaboration

cited authors

  • Vergote, I., Finkler, N. J., Hall, J. B., Melnyk, O., Edwards, R. P., Jones, M., Meng, L., Brown, G. L., Rankin, E. M., Burke, J. J., II, Rose, P. G.

Publication Date

  • May 20, 2009

webpage

published in

category

volume

  • 27

issue

  • 15

WoS Citations

  • 0

WoS References

  • 0